Karachi, May 20, 2024 : Lucky Core Industries Limited (LCI) is pleased to announce that on May 17, 2024, the Company
executed Asset Purchase Agreements with Pfizer Pakistan Limited and Pfizer Inc., a leading global
pharmaceutical group, for the acquisition of certain assets.
The assets being acquired by LCI through this transaction include a manufacturing facility owned by
Pfizer Pakistan Limited located in Karachi, along with a portfolio of well-established pharmaceutical
brands, namely Ansaid, Ponstan, Ponstan Forte, Basoquin, Deltacortril, Lysovit, Corex-D and
Mycitracin, as well as trademarks associated with the said pharmaceutical products (either through an
outright assignment of trademarks or a perpetual license to use the relevant trademarks). These
leading brands are primary care products in the therapeutic areas including, pain, skin infections, and
vitamin deficiencies, and have strong potential for growth in the market.
Chief Executive LCI, Asif Jooma, commented: “This acquisition marks a significant milestone in our
journey towards accelerating growth of our Pharmaceuticals business. By adding these established
brands to our portfolio, we will further enrich the lives of those around us by continuing to deliver
quality medicines and healthcare products, while expanding our manufacturing base, diversifying our
product offerings, and implementing synergies to strengthen our position in the marketplace.”
The transaction is now set to move ahead, subject to requisite approvals and satisfaction of conditions
in the Asset Purchase Agreements. We look forward to completing the transaction and integrating
these assets into our operations, further solidifying our position as a leading player in the market.
ADVERTISEMENT
